JJ
PHGE icon

Johnson & Johnson’s BiomX PHGE Stock Holding History

Johnson & Johnson’s Portfolio PHGE Stock Details PHGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,098
Closed -$50.9K – 19
2025
Q3 		$50.9K Hold
5,098
– – 0.01% 19
2025
Q2 		$42.6K Hold
5,098
– – 0.01% 19
2025
Q1 		$53.8K Hold
5,098
– – 0.02% 19
2024
Q4 		$70.7K Sell
5,098
-5,024
-50% -$71.5K 0.02% 19
2024
Q3 		$196K Hold
10,122
– – 0.05% 18
2024
Q2 		$646K Hold
10,122
– – 0.16% 17
2024
Q1 		$865K Sell
10,122
-1,106
-10% -$58.2K 0.02% 17
2023
Q4 		$597K Hold
11,228
– – 0.01% 19
2023
Q3 		$751K Hold
11,228
– – 0.28% 18
2023
Q2 		$768K Hold
11,228
– – 0.24% 16
2023
Q1 		$651K Hold
11,228
– – 0.21% 17
2022
Q4 		$398K Hold
11,228
– – 0.12% 17
2022
Q3 		$725K Hold
11,228
– – 0.21% 17
2022
Q2 		$1.56M Hold
11,228
– – 0.4% 16
2022
Q1 		$4.12M Hold
11,228
– – 0.78% 14
2021
Q4 		$3.41M Hold
11,228
– – 0.39% 15
2021
Q3 		$6.53M Buy
+11,228
New +$8.7M 0.57% 13

Other funds holding PHGE

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Johnson & Johnson's PHGE Position: Q4 2025 in Review

Johnson & Johnson sold out of BiomX (PHGE) in Q4 2025, closing a stake of 5,098 shares — an estimated $50.9K sold.

Johnson & Johnson first reported a position in PHGE in Q3 2021 and held it in 17 quarters. The position peaked at $6.53M in Q3 2021. 11 funds tracked by Wall St. Rank hold PHGE as of Q4 2025.

  • Johnson & Johnson reported no remaining BiomX position as of Q4 2025 after selling out during the quarter.
  • Johnson & Johnson sold 5,098 BiomX shares in Q4 2025, an estimated $50.9K.
  • Johnson & Johnson first reported a position in BiomX in Q3 2021 and held it in 17 quarters.
  • Johnson & Johnson's BiomX position peaked at $6.53M in Q3 2021.
  • 11 funds tracked by Wall St. Rank held BiomX as of Q4 2025.

Based on Johnson & Johnson's 13F filing for Q4 2025, filed 13 Feb 2026.